ZetrOZ Systems, developer of sustained acoustic medicine (SAM) — an FDA-cleared home-use ultrasound device designed to help reduce pain associated with tendon, ligament, and muscle injuries — has received funding from the National Institute of Health (NIH) to research new ways to reduce arthritic pain utilizing non-surgical, non-narcotic technology.
Arthritic pain has been primarily managed by nonsteroidal anti-inflammatory drugs (NSAIDs), namely diclofenac. Diclofenac, which is administered topically, is limited in its efficacy due to its limited ability to penetrate the skin.
Results Suggest 380% Enhanced Delivery
New findings from researchers at the University of Cincinnati suggest SAM technology’s ability to deliver NSAIDs locally and effectively, demonstrating 380% enhanced delivery compared to existing technology for the treatment of joint pain, a media release from ZetrOZ Systems explains.
“Targeted and localized drug delivery is the holy grail for many therapeutic agents, and this has been demonstrated with small-molecule therapeutics, combined with our latest sam 2.0.
“The research community is excited by the findings, as it has broad implications for the local delivery of therapeutic agents without the need for oral delivery.”
— Dr George Lewis, CEO of ZetrOZ Systems
Study Looks at SAM’s Delivery Method
The study published in the Journal of Therapeutic Delivery, investigated the use of sam 2.0, “a multi-hour, wearable, localized, sonophoresis transdermal drug delivery device for the penetration enhancement of diclofenac through the skin.”
In addition to the increased delivery of diclofenac, use of sam 2.0 medical technology resulted in an increased depth of penetration of the skin by 32%. Findings suggest that sustained acoustic medicine can be used as an effective transdermal drug-delivery device for nonsteroidal anti-inflammatory drugs, the release continues.
“Our collaborations with the top research institutions such as the University of Cincinnati foster continuous innovation on sustained acoustic medicine in the treatment of chronic pain.”
— Dr George Lewis
[Source(s): ZetrOZ Systems, PR Newswire]
This Device Offers a Pain Management and Surgery Alternative